Australia markets close in 2 hours 49 minutes
  • ALL ORDS

    7,409.60
    +36.40 (+0.49%)
     
  • ASX 200

    7,173.50
    +44.70 (+0.63%)
     
  • AUD/USD

    0.7103
    -0.0007 (-0.10%)
     
  • OIL

    111.09
    +1.32 (+1.20%)
     
  • GOLD

    1,859.40
    -6.00 (-0.32%)
     
  • BTC-AUD

    42,379.41
    +882.05 (+2.13%)
     
  • CMC Crypto 200

    671.09
    +15.26 (+2.33%)
     
  • AUD/EUR

    0.6629
    +0.0011 (+0.16%)
     
  • AUD/NZD

    1.0929
    -0.0072 (-0.65%)
     
  • NZX 50

    11,239.98
    -7.05 (-0.06%)
     
  • NASDAQ

    11,769.84
    -264.44 (-2.20%)
     
  • FTSE

    7,484.35
    -29.09 (-0.39%)
     
  • Dow Jones

    31,928.62
    +48.38 (+0.15%)
     
  • DAX

    13,919.75
    -255.65 (-1.80%)
     
  • Hang Seng

    20,109.06
    -3.04 (-0.02%)
     
  • NIKKEI 225

    26,713.08
    -35.06 (-0.13%)
     

What's Behind Bristol Myers Squibb's Latest Partnership?

·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Bristol Myers Squibb (NYSE: BMY) has made some big acquisitions in the past, and it's now hinting that more deals could be on the way. The pharmaceutical giant recently announced a smaller licensing agreement with Century Therapeutics (NASDAQ: IPSC) instead of a big acquisition. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss what's behind Bristol Myers Squibb's latest partnership.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting